324 related articles for article (PubMed ID: 16924054)
1. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
[TBL] [Abstract][Full Text] [Related]
2. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
3. Muir-Torre syndrome: Diagnostic and screening guidelines.
Jones B; Oh C; Mangold E; Egan CA
Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
5. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
6. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
[TBL] [Abstract][Full Text] [Related]
7. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
[TBL] [Abstract][Full Text] [Related]
8. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics.
Orta L; Klimstra DS; Qin J; Mecca P; Tang LH; Busam KJ; Shia J
Am J Surg Pathol; 2009 Jun; 33(6):934-44. PubMed ID: 19342947
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
[TBL] [Abstract][Full Text] [Related]
10. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
[TBL] [Abstract][Full Text] [Related]
11. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome.
Harrington CR; Egbert BM; Swetter SM
Dermatol Surg; 2004 May; 30(5):817-9. PubMed ID: 15099333
[TBL] [Abstract][Full Text] [Related]
12. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
14. [Multiple sebaceous tumors with colon cancer--Muir-Torre syndrome].
Vajda A; Scharrer K; Baló-Banga JM
Orv Hetil; 2003 May; 144(20):985-9. PubMed ID: 12830729
[TBL] [Abstract][Full Text] [Related]
15. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
[TBL] [Abstract][Full Text] [Related]
16. Sebaceous gland adenoma of the tarsal conjunctiva in a patient with Muir-Torre syndrome.
Font RL; Rishi K
Ophthalmology; 2003 Sep; 110(9):1833-6. PubMed ID: 13129885
[TBL] [Abstract][Full Text] [Related]
17. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
19. Muir-Torre syndrome: a case report and review of the literature.
Pettey AA; Walsh JS
Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
[TBL] [Abstract][Full Text] [Related]
20. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
